Hematology

The Phase II CONCEPT trial has demonstrated that an isatuximab-based combination therapy achieves unprecedented rates of minimal residual disease negativity in patients with high-risk newly diagnosed multiple myeloma.

A large European analysis confirms circulating tumour cells (CTCs) as an independent prognostic biomarker in newly diagnosed multiple myeloma.

A new analysis of early total therapy clinical trials has revealed that up to one-third of patients with newly diagnosed multiple myeloma may achieve long-term survival.

A new UK clinical trial has found that children undergoing stem cell transplants may safely receive fewer blood transfusions.

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies…

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with frailty and overall survival in newly diagnosed multiple myeloma.

At COMy 2025, researchers highlighted barriers to EMA-approved CAR-T cell therapy access due to age, comorbidities, and inequality.